RT Journal Article
SR Electronic
T1 Epidemiological inferences from serological responses to cross-reacting pathogens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.12.24311852
DO 10.1101/2024.08.12.24311852
A1 O’Driscoll, Megan
A1 Hozé, Nathanaël
A1 Lefrancq, Noémie
A1 Ribeiro Dos Santos, Gabriel
A1 Hoinard, Damien
A1 Rahman, Mohammed Ziaur
A1 Paul, Kishor Kumar
A1 Naser Titu, Abu Mohd
A1 Alam, Mohammad Shafiul
A1 Hossain, Mohammad Enayet
A1 Vanhomwegen, Jessica
A1 Cauchemez, Simon
A1 Gurley, Emily S
A1 Salje, Henrik
YR 2024
UL http://medrxiv.org/content/early/2024/08/12/2024.08.12.24311852.abstract
AB Multiplex immunoassays are facilitating the parallel measurement of antibody responses against multiple antigenically-related pathogens, generating a wealth of high-dimensional data which depict complex antibody-antigen relationships. In this study we develop a generalizable analytical framework to maximise inferences from multi-pathogen serological studies. We fit the model to measurements of IgG antibody binding to 10 arboviral pathogens from a cross-sectional study in northwest Bangladesh with 1,453 participants. We used our framework to jointly infer the prevalence of each pathogen by location and age, as well as the levels of between-pathogen antibody cross-reactivity. We find evidence of endemic transmission of Japanese encephalitis virus as well as recent outbreaks of dengue and chikungunya viruses in this district. Our estimates of antibody cross-reactivity were highly consistent with phylogenetic distances inferred from genetic data. Further, we demonstrated how our framework can be used to identify the presence of circulating cross-reactive pathogens that were not directly tested for, representing a potential opportunity for the detection of novel emerging pathogens. The presented analytical framework will be applicable to the growing number of multi-pathogen studies and will help support the integration of serological testing into disease surveillance platforms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from the European Union Horizon 2020 Research and Innovation Programme (804744)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical review boards at CDC, icddr,b (PR-13001), Johns Hopkins Bloomberg School of Public Health, and Institut Pasteur. We obtained informed consent, and assent when appropriate, from all individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSimulated data and de-identified data are available in the associated GitHub repository https://github.com/meganodris/MultiSero